Skip to main content
Clinical Trials/NCT00764842
NCT00764842
Terminated
Not Applicable

Post-Market Study: The Efficacy of the CLP® Hip

Encore Medical, L.P.1 site in 1 country61 target enrollmentJanuary 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoarthritis
Sponsor
Encore Medical, L.P.
Enrollment
61
Locations
1
Primary Endpoint
The survivorship and efficacy of the Encore CLP® Hip stem
Status
Terminated
Last Updated
15 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the survivorship and efficacy of the Encore CLP® Hip stem in a group of no more than 200 patients from whom data has already been collected.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
February 2011
Last Updated
15 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients must be 18 years of age or older.
  • Noninflammatory degenerative joint disease including
  • Osteoarthritis of the natural femoral head
  • Avascular necrosis of the natural femoral head
  • Rheumatoid arthritis
  • Correction of functional deformities
  • Femoral fracture
  • Patients must be able and willing to complete all study-related visits.

Exclusion Criteria

  • Anyone who is under 18 years of age
  • Infection or sepsis
  • Insufficient bone quality which may affect the stability of the implant
  • Muscular, neurological or vascular deficiencies, which compromise the affected extremity
  • Skeletally immature patients and cases where there is a loss of abductor musculature, poor bone stock, poor skin coverage around hip joint which would make the procedure unjustifiable
  • Osteomyelitis
  • Rapid joint destruction or bone absorption apparent on roentgenogram
  • Pathological conditions of the acetabulum which would prevent achieving proper range of motion, appropriate head stability, and/or a well-seated and supported smooth articulation of the head within the acetabulum
  • Alcoholism or other addictions
  • Materials sensitivity

Outcomes

Primary Outcomes

The survivorship and efficacy of the Encore CLP® Hip stem

Time Frame: 2 year

Study Sites (1)

Loading locations...

Similar Trials